Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8266990 | 0.84 | NPSR1 (0.37) | NPSR1HCAR2NPC1RAB9AALDH1A1 | |
| SCHEMBL31630478 | 0.83 | GRIA1 (0.32) | NPSR1GRIA1GRIA3LMNABRD4 | |
| Hydrochloric Acid SCHEMBL31630254 | 0.81 | GRIA1 (0.31) | NPSR1GRIA1GRIA3LMNA | |
| SCHEMBL285480 | 0.80 | TLR8 (0.36) | — | |
| SCHEMBL13067323 | 0.78 | NPSR1 (0.34) | NPSR1HCAR2NPC1RAB9AALDH1A1 | |
| SCHEMBL13059078 | 0.78 | NPSR1 (0.37) | NPSR1HCAR2NPC1RAB9AALDH1A1 | |
| SCHEMBL16009045 | 0.78 | LMNA (0.34) | NPSR1HCAR2NPC1RAB9AALDH1A1 | |
| SCHEMBL13059077 | 0.78 | NPSR1 (0.34) | NPSR1HCAR2NPC1RAB9AALDH1A1 | |
| SCHEMBL17000226 | 0.75 | GRIA1 (0.33) | NPSR1HCAR2NPC1RAB9AALDH1A1 | |
| SCHEMBL3906075 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20240262827-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11970497-B2 | Tricyclic AKR1C3 dependent KARS inhibitors | NOVARTIS AG (CH) | 2024-04-30 | — | — | US | disclosed |
| EP-4349839-A2 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| EP-4013500-B1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS AG (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20220315582-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4013500-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021005586-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS AG (CH) | 2021-01-14 | — | — | WO | disclosed |
| EP-3541803-B1 | TRIAZOLE PYRIDYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10689367-B2 | Triazole pyridyl compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190300507-A1 | TRIAZOLE PYRIDYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315582-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | NPSR1 3030/4885HCAR2 134/4885NPC1 291/4885 |
| US-20190300507-A1 | TRIAZOLE PYRIDYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, APLNR | NPSR1 293/4885HCAR2 137/4885NPC1 2691/4885 |
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | NPSR1 3030/4885HCAR2 134/4885NPC1 291/4885 |
| US-11970497-B2 | Tricyclic AKR1C3 dependent KARS inhibitors | AKR1C2, AKR1B1, AKR1C1 | NPSR1 3030/4885HCAR2 134/4885NPC1 291/4885 |
| US-20240262827-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | NPSR1 3030/4885HCAR2 134/4885NPC1 291/4885 |
| US-10689367-B2 | Triazole pyridyl compounds as agonists of the APJ receptor | TBXA2R, AGTR1, APLNR | NPSR1 281/4885HCAR2 129/4885NPC1 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.